Representativeness in Premarketing vs Postmarketing US Food and Drug Administration Trials

被引：1

|

作者：

Unger, Joseph M. ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-C102,POB 19024, Seattle, WA 98109 USA

来源：

JAMA NETWORK OPEN | 2021年 / 4卷 / 04期

关键词：

D O I：

10.1001/jamanetworkopen.2021.7159

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页数：3

相关论文

共 50 条

[41] US Food and Drug Administration pushed to change
McCarthy, M
LANCET, 2006, 367 (9523): : 1643 - 1644
[42] Increasing Transparency at the US Food and Drug Administration
Steinbrook, Robert
JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1146 - 1147
[43] The US Food and Drug Administration and Emergency Contraception
Fox, Anthony W.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL MEDICINE, 2005, 19 (03): : 139 - 140
[44] Crisis deepens at the US Food and Drug Administration
Lenzer, J
BRITISH MEDICAL JOURNAL, 2004, 329 (7478): : 1308 - 1308
[45] US Food and Drug Administration gets it right
Grove, ML
BRITISH MEDICAL JOURNAL, 2002, 325 (7367): : 776 - 776
[46] Moving the US Food and Drug Administration Forward
Perlmutter, Joel S.
ANNALS OF INTERNAL MEDICINE, 2021, 174 (11) : 1626 - 1627
[47] Cyberpharmacies and the role of the US Food And Drug Administration
Henney, Jane E.
JOURNAL OF MEDICAL INTERNET RESEARCH, 2001, 3 (01) : 7 - 20
[48] The US Food and Drug Administration and Emergency Contraception
Anthony W. Fox
International Journal of Pharmaceutical Medicine, 2005, 19 (3) : 139 - 140
[49] Use of propensity score methodology in cardiovascular device trials: US Food and Drug Administration perspectives
Muni, N
Yue, L
VALUE IN HEALTH, 2005, 8 (06) : A111 - A111
[50] Blueprint for Transparency at the US Food and Drug Administration
McClellan, Courtney
JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 1 - 1

← 1 2 3 4 5 →